Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,348 recruiting studies in this area right now.
By phase
- Not applicable9,612
- Phase 24,442
- Phase 12,685
- Phase 1/Phase 21,654
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer648
- Cancer636
- Colorectal Cancer476
- Lung Cancer421
- Ovarian Cancer341
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma259
- Solid Tumor245
- Advanced Solid Tumor231
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors208
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center458
- Fudan University306
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital129
Where studies are running
- California1,401
- Texas636
- Arizona508
- Florida439
- Alabama430
- New York406
- Massachusetts340
- Maryland330
- New Jersey275
- Pennsylvania236
Recruiting studies20,348 total
- NCT05574673Recruiting
Study of DNA repair traits in ovarian cancer patients
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
København Ø, Region SjællandAges 18–100 - NCT05592015RecruitingPhase 2
Ruxolitinib for T-cell large granular leukemia
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
Boston, MassachusettsAges 18 years+ - NCT05587439Recruiting
Study of inherited genetic risk in lung and related cancers
This study looks for inherited (family-passed) genetic changes that may raise the risk of lung cancer and related thoracic cancers. It may help people and families understand their genetic risk by collecting health information and sometimes specimens from patients and relatives.
Boston, MassachusettsAges 18 years+ - NCT05576974RecruitingPhase 2
Test a dye used during surgery to find head and neck cancer
This trial tests whether a single dose of an imaging dye (given during surgery) can help doctors find the unknown origin of head and neck cancer and check safety. It may help guide surgery and biopsies when the primary cancer location hasn’t been identified.
Dallas, TexasAges 18–99 - NCT05588700Recruiting
Exercise program to reduce long-term cancer fatigue
This trial studies whether a structured physical activity program can reduce ongoing (long-term) fatigue in men with metastatic testicular cancer. It likely helps by improving fitness and energy during and after first-line chemotherapy.
AngersAges 18 years+ - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Gilbert, ArizonaAges 18 years+ - NCT05588648RecruitingPhase 1/Phase 2
Vactosertib for recurrent or progressive bone cancer
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
Cleveland, OhioAges 12 years+ - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT05583617RecruitingPhase 1/Phase 2
Testing multiple treatments for multiple myeloma after prior therapy
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Randwick, New South WalesAges 18 years+ - NCT05570422RecruitingPhase 1
Safety and early benefits of an injection plus radiation for cervical cancer
This Phase 1 study tests whether KRC-01, given by injection into the tumor, is safe and tolerable when combined with standard chemoradiation for locally advanced cervical cancer. It also looks for early signs that the treatment can shrink tumors.
ChandigarhAges 18 years+ - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Tampa, FloridaAges 18 years+ - NCT05557695Recruiting
Acalabrutinib patient study for early access CLL in the UK
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
AylesburyAges 18–130 - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Phoenix, ArizonaAges Any age - NCT05584800RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
Beijing, Beijing MunicipalityAges 18–75 - NCT05552755RecruitingPhase 1/Phase 2
Drug trial for FAP to reduce pre-cancer growth
This early-phase trial studies REC-4881 in adults with familial adenomatous polyposis (FAP), a condition that causes many colon/rectum and duodenal polyps. It aims to see whether the treatment can safely help control or shrink polyp growth in people who have had bowel surgery.
Scottsdale, ArizonaAges 18 years+ - NCT05549297RecruitingPhase 3
Tebentafusp plus choice of treatment for advanced melanoma
This Phase 3 study compares tebentafusp treatment against the doctor’s choice of standard options in people with previously treated advanced melanoma. It aims to see which approach works better for controlling the cancer and improving outcomes.
Phoenix, ArizonaAges 18 years+ - NCT05573126RecruitingPhase 1/Phase 2
Study of EP0062 for advanced breast cancer with AR+ and ER+
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
New Haven, ConnecticutAges 18 years+ - NCT05573893Recruiting
Real-world study of trastuzumab deruxtecan for HER2 breast cancer
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
AmbergAges 18–130 - NCT05587049Recruiting
Testing an oral medicine plus azacitidine to improve AML disease
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Medellín, AntioquiaAges 18 years+ - NCT05586074RecruitingPhase 3
Test drug HEC73543 against chemo for FLT3-mutated AML
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
HanzhouAges 18 years+ - NCT05098184RecruitingEarly Phase 1
Study TIL treatment for advanced melanoma using harvested tumor cells
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
ShanghaiAges 18–75 - NCT05142475RecruitingEarly Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
ShanghaiAges 18–75 - NCT05098171RecruitingEarly Phase 1
Study TIL cell therapy for advanced gynecologic cancers
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03833921RecruitingPhase 2
Testing abiraterone and prednisone for metastatic prostate cancer by race
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Houston, TexasAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,348 recruiting oncology studies from the U.S. registry right now, out of 31,535 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.